TY - JOUR
T1 - Pulmonary Artery Denervation for Pulmonary Arterial Hypertension
T2 - A Sham-Controlled Randomized PADN-CFDA Trial
AU - Zhang, Hang
AU - Wei, Yongyue
AU - Zhang, Caojin
AU - Yang, Zhenwen
AU - Kan, Jing
AU - Gu, Heping
AU - Fan, Fenling
AU - Gu, Hong
AU - Wang, Qiguang
AU - Xie, Dujiang
AU - Zhang, Gangcheng
AU - Guo, Xiaomei
AU - Yin, Yuehui
AU - Jin, Bowen
AU - Zhou, Hongmei
AU - Yang, Ziyang
AU - Wang, Zhouming
AU - Xin, Yu
AU - Zhang, Chen
AU - Meng, Lili
AU - Wang, Xiaoyu
AU - Sun, Jingping
AU - Zhao, Chunxia
AU - Zhang, Juan
AU - Yan, Xiaoyan
AU - Chen, Feng
AU - Yao, Cheng
AU - Stone, Gregg W.
AU - Chen, Shao Liang
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/12/12
Y1 - 2022/12/12
N2 - Background: World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a progressive, debilitating disease. Previous observational studies have demonstrated that pulmonary artery denervation (PADN) reduces pulmonary artery pressures in PAH. However, the safety and effectiveness of PADN have not been established in a randomized trial. Objectives: The aim of this study was to determine the treatment effects of PADN in patients with group 1 PAH. Methods: Patients with WHO group 1 PAH not taking PAH-specific drugs for at least 30 days were enrolled in a multicenter, sham-controlled, single-blind, randomized trial. Patients were assigned to receive PADN plus a phosphodiesterase-5 inhibitor or a sham procedure plus a phosphodiesterase-5 inhibitor. The primary endpoint was the between-group difference in the change in 6-minute walk distance from baseline to 6 months. Results: Among 128 randomized patients, those treated with PADN compared with sham had a greater improvement in 6-minute walk distance from baseline to 6 months (mean adjusted between-group difference 33.8 m; 95% CI: 16.7-50.9 m; P < 0.001). From baseline to 6 months, pulmonary vascular resistance was reduced by −3.0 ± 0.3 WU after PADN and −1.9 ± 0.3 WU after sham (adjusted difference −1.4; 95% CI: −2.6 to −0.2). PADN also improved right ventricular function, reduced tricuspid regurgitation, and decreased N-terminal pro–brain natriuretic peptide. Clinical worsening was less (1.6% vs 13.8%; OR: 0.11; 95% CI: 0.01-0.87), and a satisfactory clinical response was greater (57.1% vs 32.3%; OR: 2.79; 95% CI: 1.37-5.82) with PADN treatment during 6-month follow-up. Conclusions: In patients with WHO group 1 PAH, PADN improved exercise capacity, hemodynamic status, and clinical outcomes during 6-month follow-up.
AB - Background: World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a progressive, debilitating disease. Previous observational studies have demonstrated that pulmonary artery denervation (PADN) reduces pulmonary artery pressures in PAH. However, the safety and effectiveness of PADN have not been established in a randomized trial. Objectives: The aim of this study was to determine the treatment effects of PADN in patients with group 1 PAH. Methods: Patients with WHO group 1 PAH not taking PAH-specific drugs for at least 30 days were enrolled in a multicenter, sham-controlled, single-blind, randomized trial. Patients were assigned to receive PADN plus a phosphodiesterase-5 inhibitor or a sham procedure plus a phosphodiesterase-5 inhibitor. The primary endpoint was the between-group difference in the change in 6-minute walk distance from baseline to 6 months. Results: Among 128 randomized patients, those treated with PADN compared with sham had a greater improvement in 6-minute walk distance from baseline to 6 months (mean adjusted between-group difference 33.8 m; 95% CI: 16.7-50.9 m; P < 0.001). From baseline to 6 months, pulmonary vascular resistance was reduced by −3.0 ± 0.3 WU after PADN and −1.9 ± 0.3 WU after sham (adjusted difference −1.4; 95% CI: −2.6 to −0.2). PADN also improved right ventricular function, reduced tricuspid regurgitation, and decreased N-terminal pro–brain natriuretic peptide. Clinical worsening was less (1.6% vs 13.8%; OR: 0.11; 95% CI: 0.01-0.87), and a satisfactory clinical response was greater (57.1% vs 32.3%; OR: 2.79; 95% CI: 1.37-5.82) with PADN treatment during 6-month follow-up. Conclusions: In patients with WHO group 1 PAH, PADN improved exercise capacity, hemodynamic status, and clinical outcomes during 6-month follow-up.
KW - 6-minute walk distance
KW - pulmonary arterial hypertension
KW - pulmonary artery denervation
KW - pulmonary artery pressure
KW - pulmonary vascular resistance
UR - https://www.scopus.com/pages/publications/85142695050
U2 - 10.1016/j.jcin.2022.09.013
DO - 10.1016/j.jcin.2022.09.013
M3 - 文章
C2 - 36121246
AN - SCOPUS:85142695050
SN - 1936-8798
VL - 15
SP - 2412
EP - 2423
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 23
ER -